Amplifi Vascular Reports Positive First-in-Human Study Outcomes, Secures $6.8M in Series A Funding, and Obtains FDA IDE Clearance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 09 2025
0mins
Source: Yahoo Finance
Positive Study Results: Amplifi Vascular announced successful first-in-human study results for its Vein Dilation System, which showed rapid vein enlargement and improved outcomes for arteriovenous fistula (AVF) creation in hemodialysis patients.
Funding and FDA Approval: The company closed a $6.9 million Series A financing round and received FDA approval for its Investigational Device Exemption, allowing it to start a U.S. clinical investigation to further evaluate the system's safety and performance.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
